❤️

Valvular Heart Disease Management

Jun 28, 2025

View transcript

Overview

This Medical Grand Rounds centered on the rapid advancements in valvular heart disease management, emphasizing interdisciplinary collaboration between cardiology and cardiac surgery. Experts discussed current assessment, intervention guidelines, emerging technologies, and procedural outcomes for aortic stenosis, mitral regurgitation, and tricuspid regurgitation.

Advances in Valvular Heart Disease Management

  • Approach to valvular heart disease has shifted significantly in the past 20 years, especially with new imaging and minimally invasive interventions.
  • Multidisciplinary valve teams, including non-invasive and interventional cardiologists, cardiac surgeons, and heart failure specialists, are essential for complex patient care.
  • UCSF is establishing a valve center of excellence to coordinate care and expertise.

Assessment and Guidelines for Valve Lesions

  • Assessment includes physical exam, ECG, chest x-ray, TTE, often supplemented by TEE, CT, MRI, and sometimes cardiac catheterization.
  • Severity is staged A–D; interventions typically for stage C2 and D (severe disease).
  • Surgical risk and patient comorbidities are systematically evaluated using the STS score.
  • Newest guidelines (2020) recommend multidisciplinary evaluation before intervention in all severe cases.

Aortic Stenosis: Diagnosis and Intervention

  • Severe symptomatic aortic stenosis carries high mortality; urgent referral is necessary.
  • TAVR is indicated for high/prohibitive surgical risk or age >80; SAVR preferred for patients <65; choice for ages 65–80 individualized.
  • No medical therapy exists for aortic stenosis; patients require close monitoring and timely intervention.
  • Age alone is not a contraindication for TAVR or SAVR.

Mitral Regurgitation: Diagnosis and Management

  • Primary MR (valve abnormality) is curable with repair or replacement; secondary MR (ventricular/atrial dysfunction) requires optimal GDMT first.
  • TEE is crucial for repairability assessment; mitral valve repair preferred over replacement when feasible.
  • Minimally invasive and percutaneous techniques (MitraClip, Pascal) evolving; surgical repair remains standard for primary MR unless high risk.
  • Edge-to-edge repair now preferred for secondary MR if symptoms persist after GDMT.

Tricuspid Regurgitation: Evolving Therapies

  • Severe TR has poor prognosis; majority are functional due to left heart disease or AFib.
  • Main therapy is diuretics; intervention previously limited but now includes FDA-approved transcatheter options (TriClip, Evoke).
  • Early referral and accurate assessment are critical to prevent organ failure and optimize outcomes.

Transcatheter and Surgical Innovations

  • TAVR and other transcatheter procedures have expanded, showing comparable outcomes to surgery in selected populations.
  • Advances include minimally invasive and robot-assisted repairs, combination procedures, and valve-in-valve strategies.
  • Surgical thresholds for mechanical vs. tissue valves are shifting, with tissue valves now standard for most patients over 50 due to re-intervention options.

Shared Decision-Making and Follow-Up

  • Choice between surgical vs. transcatheter intervention for ages 65–80 guided by patient preferences, expected valve durability, and individual anatomy.
  • Long-term valve durability data, especially for TAVR, are still forthcoming.
  • Regular multidisciplinary meetings ensure comprehensive patient assessment and management.

Questions and Audience Discussion

  • Durability concerns guide choice of mechanical vs. tissue valves, especially in younger patients.
  • Coronary artery disease evaluation is case-dependent and influences procedural choice.
  • Management of congenital valve disease in young patients is complex and may require multiple interventions over a lifetime.
  • AFib risk post-procedure is generally lower with transcatheter approaches, addressed surgically with maze procedure when appropriate.
  • Anticoagulation strategies mostly align between surgical and transcatheter approaches, with nuances for certain interventions and valve locations.

Decisions

  • A multidisciplinary team will assess all severe valvular heart disease cases before intervention.
  • Edge-to-edge repair is now preferred for secondary mitral regurgitation after optimized GDMT.
  • Tissue valves are recommended over mechanical valves for most patients over age 50.

Action Items

  • TBD – Valve Team: Continue regular multidisciplinary case conferences for complex valve cases.
  • TBD – UCSF Valve Center: Implement and expand protocols for early referral and comprehensive assessment.
  • TBD – AHA/UCSF: Participate in and support the Target AS initiative for standardized care and quality improvement.

Recommendations / Advice

  • Refer severe or complex valve disease patients early to a multidisciplinary valve center.
  • Ensure optimal GDMT for secondary MR before considering interventions.
  • Use multi-modality imaging and structured follow-up for all significant valve lesions.
  • Engage patients in shared decision-making, especially for ages 65–80 or those with complex anatomy or comorbidities.

Certainly! Here is a comprehensive, in-depth summary and review of the Medical Grand Rounds lecture on valvular heart disease, covering all key points and details discussed by the experts:

Comprehensive Summary and Review: Advances in Valvular Heart Disease Management

Introduction and Context

  • The lecture highlighted the remarkable evolution in the diagnosis and treatment of valvular heart disease over the past 20 years.
  • Emphasis on teamwork and collaboration between cardiology (non-invasive and interventional) and cardiac surgery.
  • UCSF’s establishment of a Valve Center of Excellence exemplifies this multidisciplinary approach.
  • The focus was on three major valvular diseases: aortic stenosis (AS), mitral regurgitation (MR), and tricuspid regurgitation (TR).
  • Three experts presented:
    • Dr. Kirsten Tolstrup (Non-invasive cardiology and imaging)
    • Dr. Sammy Elmariah (Interventional cardiology)
    • Dr. Tobias Deuse (Cardiac surgery, minimally invasive techniques)

General Principles of Valvular Heart Disease Assessment

  • Initial evaluation includes:
    • Physical examination
    • Electrocardiogram (ECG)
    • Chest X-ray
    • Transthoracic echocardiogram (TTE) — cornerstone diagnostic tool
  • Additional imaging as needed:
    • Transesophageal echocardiogram (TEE) for detailed valve morphology and repairability
    • Cardiac CT and MRI for anatomical and functional assessment
    • Stress testing (exercise or pharmacologic) especially in asymptomatic patients
    • Hemodynamic cardiac catheterization in select cases
  • Surgical risk assessment using STS score, comorbidities, and frailty evaluation.
  • Valvular disease severity staged A to D (per ACC/AHA guidelines):
    • Stage A: At risk
    • Stage B: Progressive disease
    • Stage C: Asymptomatic severe disease (C1 without LV/RV dysfunction, C2 with LV/RV dysfunction)
    • Stage D: Symptomatic severe disease
  • Intervention generally indicated for stages C2 and D.
  • Importance of detailed symptom assessment, as patients often underreport or mask symptoms.
  • Multidisciplinary valve team evaluation is a class I recommendation for all severe valvular disease cases when intervention is considered.
  • Referral to specialized valve centers is encouraged, especially for complex or multi-valvular disease.

Aortic Stenosis (AS)

Epidemiology and Pathophysiology

  • Most common valvular disease in elderly; prevalence ~4% in those >75 years.
  • Congenital bicuspid aortic valve affects 1-2% of population, often leading to earlier disease.
  • Rheumatic AS is rare in developed countries, usually accompanied by mitral valve disease.

Clinical Importance

  • Severe symptomatic AS has a dismal prognosis without intervention (5-year survival ~3%).
  • Early detection and timely intervention are critical.

Diagnostic Evaluation

  • Echocardiography assesses:
    • Valve morphology and calcification
    • Severity of stenosis (valve area, gradients)
    • LV and RV size and function
    • Presence of other valve lesions (aortic or mitral regurgitation)
    • Pulmonary hypertension
    • Aortic root anatomy (important for procedural planning)
  • TTE is usually sufficient; TEE and CT used for detailed anatomy and procedural planning.

Treatment Guidelines

  • No effective medical therapy for AS.
  • Intervention indicated for:
    • Symptomatic severe AS (class I)
    • Asymptomatic severe AS with LV dysfunction or dilation (class I)
  • Choice of intervention depends on surgical risk and age:
    • High or prohibitive surgical risk → TAVR preferred
    • Age <65 → Surgical aortic valve replacement (SAVR) preferred
    • Age >80 → TAVR preferred
    • Age 65-80 → Individualized decision based on anatomy, comorbidities, and patient preference
  • Other factors influencing choice:
    • Access site suitability for TAVR
    • Risk of pacemaker implantation
    • Presence of aortic root dilation (may favor surgery)
  • Close follow-up with echocardiography every 6 months for asymptomatic severe AS.
  • Stress testing safe in asymptomatic patients to unmask symptoms; contraindicated in symptomatic AS.

Advances in TAVR

  • TAVR initially approved for inoperable/high-risk patients; now expanded to intermediate and low-risk patients.
  • Landmark trials (PARTNER 1B, 1A, 2, 3) demonstrated non-inferiority or superiority of TAVR compared to surgery in selected populations.
  • Five-year data show comparable survival and valve hemodynamics.
  • Ongoing studies evaluating TAVR in asymptomatic and moderate AS.
  • Despite advances, only ~50% of eligible patients receive treatment, highlighting need for improved identification and referral.
  • The AHA Target AS Initiative aims to improve quality and timeliness of AS care nationally.

Mitral Regurgitation (MR)

Types of MR

  • Primary MR: Structural valve abnormality (degenerative, prolapse, chordal rupture).
    • Surgical repair is curative.
  • Secondary (functional) MR: Normal valve structure but regurgitation due to LV or left atrial dilation/dysfunction.
    • Valve intervention is not curative; treatment focuses on underlying heart failure.

Diagnostic Evaluation

  • TTE assesses:
    • LV size, volume, and systolic function
    • Left atrial size (chronicity marker)
    • Valve morphology (leaflets, chordae, papillary muscles, annulus)
    • Severity of MR
  • TEE essential for detailed valve anatomy and repairability assessment.
  • Quantitative grading of MR severity critical; intervention usually reserved for severe MR.
  • Volume status optimization important before assessment, as volume overload can exaggerate MR severity.

Treatment Guidelines

  • Primary MR:
    • Surgery is first-line treatment; repair preferred over replacement.
    • Indications: symptomatic severe MR or asymptomatic with LV dilation/dysfunction.
    • Referral to centers with high repair expertise is essential.
    • Transcatheter edge-to-edge repair (MitraClip) reserved for high/prohibitive surgical risk patients (class IIa).
  • Secondary MR:
    • Optimal guideline-directed medical therapy (GDMT) for heart failure is first-line.
    • Intervention considered only if symptoms persist despite GDMT (usually after 3 months).
    • Edge-to-edge repair preferred over surgery (class IIa).
    • Surgical repair less durable; replacement may be favored if surgery is performed.
  • Medical therapy with vasodilators for primary MR without hypertension is contraindicated (class III).

Advances in Transcatheter Therapies

  • MitraClip and Edwards Pascal systems have improved outcomes with newer generations showing <2% residual moderate/severe MR.
  • Ongoing trials (e.g., Repair MR trial) evaluating edge-to-edge repair in intermediate-risk patients.
  • Multidisciplinary heart failure involvement critical in secondary MR management.

Tricuspid Regurgitation (TR)

Epidemiology and Pathophysiology

  • Historically “forgotten valve,” now recognized as important with poor prognosis if severe and untreated.
  • ~80% of severe TR is functional, often secondary to left heart disease, atrial fibrillation, pulmonary hypertension, or RV dysfunction.
  • Primary TR less common (e.g., leaflet prolapse).

Diagnostic Evaluation

  • Challenging to quantify severity accurately; requires multi-modality imaging.
  • Assess:
    • TR severity
    • Right atrial and ventricular size and function
    • Pulmonary hypertension
    • Inferior vena cava (IVC) hemodynamics
  • TEE and CT used for detailed morphology and procedural planning.
  • Volume status optimization critical for accurate assessment.

Treatment Guidelines and Advances

  • Medical therapy mainly diuretics to manage volume overload.
  • Surgical intervention traditionally limited due to high risk and poor outcomes.
  • 2020 guidelines had only one class I indication: TR surgery during left-sided valve surgery.
  • Recent FDA approvals of transcatheter devices:
    • TriClip (edge-to-edge repair) improves quality of life but no mortality benefit at 1 year.
    • Evoke transcatheter tricuspid valve replacement shows near elimination of TR and promising early outcomes.
  • Early referral before RV failure and end-organ damage is crucial.
  • Multidisciplinary evaluation essential.

Surgical Innovations and Minimally Invasive Techniques (Dr. Tobias Deuse)

Mitral Valve Surgery

  • Majority of degenerative mitral valves repaired rather than replaced.
  • Minimally invasive right thoracic incisions (~1.5-2 inches) used for mitral procedures.
  • “Respect” approach: preserve leaflet tissue, replace ruptured chordae with Gore-Tex neochordae anchored to papillary muscles.
  • Annuloplasty ring implanted to stabilize repair.
  • Repair complexity classified (simple to complex) based on leaflet segments involved.
  • Complex cases (e.g., Barlow’s disease) may require limited resection.
  • Replacement reserved for irreparable valves (e.g., severe endocarditis, fibrosis post-MitraClip).
  • Combined surgical and transcatheter approaches used in select cases (e.g., TAVR valve-in-valve with anterior leaflet resection).

Aortic Valve Surgery

  • Minimally invasive approaches with smaller incisions.
  • Standard surgical replacement for bicuspid valves or younger patients.
  • Tissue valves preferred over mechanical valves in most cases due to re-intervention options.

Tricuspid Valve Surgery

  • Same minimally invasive access as mitral valve.
  • Repair with annuloplasty ring preferred.
  • Replacement reserved for severe or combined cases.
  • Beating heart surgery possible for isolated tricuspid cases.

Key Discussion Points and Audience Q&A

Valve Durability and Age Considerations

  • Tissue valves generally last 10-15 years, longer in older patients, shorter in younger due to metabolic activity.
  • Mechanical valves have longer durability but require lifelong anticoagulation.
  • TAVR valve durability data limited; conservative estimate ~10 years.
  • For patients 65-80, shared decision-making is essential considering durability, re-intervention options, and patient preferences.
  • Younger patients (<65) usually recommended for surgery due to durability concerns and future valve-in-valve options.

Coronary Artery Disease (CAD) and Valve Disease

  • CAD evaluation individualized; CT calcium scoring and angiography used as needed.
  • Presence of significant CAD may influence choice of surgical vs. transcatheter approach.
  • Hybrid procedures (CABG + valve surgery) considered for proximal LAD lesions.
  • Minimally invasive mitral surgery preferred unless combined CABG needed.

Congenital Valve Disease

  • Young patients with congenital valve disease often require multiple interventions due to growth and valve longevity.
  • Transcatheter therapies considered as bridge to transplantation or to delay surgery.

Atrial Fibrillation (AFib) and Valve Procedures

  • TAVR associated with low periprocedural AFib risk.
  • Surgical mitral repair often combined with maze procedure and left atrial appendage closure to reduce AFib burden.
  • AFib contributes to annular dilation and TR; rhythm control may improve TR outcomes.
  • Anticoagulation strategies similar between surgical and transcatheter approaches; usually aspirin or dual antiplatelet therapy post-procedure, with anticoagulation for valve replacements.

Summary and Take-Home Messages

  • Valvular heart disease management has transformed with advances in imaging, minimally invasive surgery, and transcatheter therapies.
  • Multidisciplinary valve teams are essential for optimal patient assessment and treatment planning.
  • Aortic stenosis: TAVR and SAVR have complementary roles based on age, risk, and anatomy.
  • Mitral regurgitation: Surgical repair remains gold standard for primary MR; transcatheter repair preferred for secondary MR after GDMT.
  • Tricuspid regurgitation: Emerging transcatheter therapies offer new hope; early intervention before RV failure is key.
  • Tissue valves favored over mechanical valves in most patients >50 due to re-intervention options.
  • Shared decision-making with patients is critical, especially in the 65-80 age group.
  • Ongoing clinical trials and initiatives (e.g., Target AS) aim to improve care delivery and long-term outcomes.

If you want, I can also help you create a detailed study guide or organize this information into sections for easier review. Just let me know!

Full transcript